BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2021 8:09:41 AM | Browse: 753 | Download: 1784
 |
Received |
|
2021-02-22 22:31 |
|
Peer-Review Started |
|
2021-02-22 22:36 |
|
First Decision by Editorial Office Director |
|
2021-05-03 01:06 |
|
Return for Revision |
|
2021-05-03 01:06 |
|
Revised |
|
2021-05-12 17:45 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-08-10 03:00 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-08-10 06:39 |
|
Articles in Press |
|
2021-08-10 06:39 |
|
Edit the Manuscript by Language Editor |
|
2021-08-23 02:06 |
|
Typeset the Manuscript |
|
2021-09-17 02:37 |
|
Publish the Manuscript Online |
|
2021-09-22 08:09 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Hepatitis C virus failure to treatment: Clinical utility of testing resistance associated substitutions
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ezequiel Ridruejo, Matías Javier Pereson, Diego M Flichman and Federico Alejandro Di Lello |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Federico Alejandro Di Lello, PhD, Research Scientist, Teacher, Facultad de Farmacia y Bioquímica, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Universidad de Buenos Aires, Junin 9564 Piso, RA-1113 Buenos Aires, Ciudad Autónoma de Buenos Aires 1113, Argentina. fadilello@ffyb.uba.ar |
| Key Words |
Hepatitis C virus; Treatment failure; Resistance; Direct-acting antiviral |
| Core Tip |
The presence of resistance-associated substitutions (RAS) to hepatitis C virus (HCV) treatment is a frequent event. Direct-acting antiviral (DAA) treatment has represented a milestone in the antiviral therapy of HCV chronic infection. The role of RAS in sustained virological response remains a controversial issue. We herein discuss the clinical utility of testing RAS in the era of pangenotypic DAA drugs. |
| Publish Date |
2021-09-22 08:09 |
| Citation |
Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus failure to treatment: Clinical utility of testing resistance associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 |
| URL |
https://www.wjgnet.com/1948-5182/full/v13/i9/1069.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v13.i9.1069 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
